Search

everythinglearnresearchcommunity

for

Search:↓

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A 19-year-old experienced significantly low testosterone levels after one month of taking finasteride. Suggestions included checking test units, retesting, and exploring other potential causes.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.

Finasteride effectively maintained hairline stability for 11 years with no side effects. Consistency and early treatment were key to success.

A user's experience of using Fin, Min and Microneedle treatments to help thicken their hair before undergoing a Hair Transplant (HT) procedure. The conversation also includes discussion about the results post-HT, including pictures.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

Finasteride effectively treated hormonal acne for multiple users, including the original poster. Topical treatments like Winlevi are effective but expensive and not always covered by insurance.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

A 19-year-old male shared progress pictures showing hair regrowth on his scalp after starting a treatment with Minoxidil and Finasteride on November 24th. He noted improved hair texture and a halt in hair shedding for the past two weeks.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A 26-year-old male experienced hair thinning since age 18 and tried various treatments, including topical minoxidil, oral finasteride, and a hair transplant. He is currently using topical finasteride, minoxidil, tretinoin, hydrocortisone, and oral dutasteride, and is satisfied with the results 6.5 months post-transplant.

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

A 20-year-old male is frustrated with his dermatologist for refusing to prescribe DHT blockers like finasteride or dutasteride, instead pushing for a hair transplant despite ongoing hair thinning. The user feels dismissed and unreasonably treated, and is advised by another user to find a better dermatologist and consider finasteride or dutasteride for effective treatment.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

A user is concerned about hair thinning and is using minoxidil, considering finasteride, and planning blood tests to rule out deficiencies. They are advised to consult a dermatologist to confirm if androgenic alopecia is the cause before starting finasteride.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A 29-year-old man experienced significant hair thickening at the front and top after using finasteride and microneedling for two months, as noticed by his hairdresser. He used 0.5 mg/day of finasteride orally, switched to a topical solution, and performed microneedling with a Derminator2 every 6-7 days.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

A user experienced a hard lump under their nipple and increased hair loss after four months of finasteride. They are concerned about the lump and plan to stop the treatment.

A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.

The user reported solid results after 5 months of using 1.25mg finasteride daily, with minimal sexual side effects and some hair regrowth at the hairline. They discontinued minoxidil due to its greasy effect on their hair.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.